Investigation of Antituberculosis Activity of Substituted Isoxazole Derivatives: A Combined Experimental and Molecular Docking Study

Abstract

Tuberculosis (TB), caused by Mycobacterium tuberculosis, is a major global health concern, particularly due to drug-resistant strains. This study investigates substituted isoxazole derivatives for their antituberculosis activity through experimental and molecular docking approaches. The synthesized compounds were evaluated against the M. tuberculosis H37Rv strain, and molecular docking was used to predict their binding with enoyl-ACP reductase (InhA). Several compounds showed significant antituberculosis activity, with some surpassing the standard drug, isoniazid. This highlights the potential of isoxazole derivatives as new antituberculosis agents.